Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company’s shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found no meaningful improvement in the overall survival for EPKINLY (epcoritamab) monotherapy when compared to standard treatments in second-line diffuse large B-cell lymphoma (DLBCL) patients.
Regardless of this shortcoming, H.C. Wainwright believes EPKINLY will likely maintain its 2023 accelerated clearance for third-line DLBCL treatment, at least until the results of two additional ongoing Phase 3 trials are released. In this context, the firm referenced a precedent set by Roche’s Columvi, which retained its accelerated approval despite missing overall survival targets in a similar patient group while expecting more study findings.
Genmab A/S is a biotechnology company specializing in oncology, developing innovative antibody-based therapies for cancer treatment. Its late-stage pipeline includes promising programs like Rina‑S and EPKINLY.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
